BRIEF published on 05/14/2024 at 22:26, 1 year 8 months ago Bausch Health Announces Updates on Norwich XIFAXAN Litigation and New FDA Submission XIFAXAN Bausch Health Patent Litigation FDA Submission Norwich Pharmaceuticals
BRIEF published on 05/14/2024 at 22:26, 1 year 8 months ago Bausch Health annonce des mises à jour sur le litige Norwich XIFAXAN et une nouvelle soumission à la FDA XIFAXAN Bausch Santé Contentieux Des Brevets Norwich Pharmaceutique Soumission À La FDA
BRIEF published on 05/14/2024 at 22:20, 1 year 8 months ago Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
BRIEF published on 05/14/2024 at 22:20, 1 year 8 months ago Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF published on 05/14/2024 at 22:20, 1 year 8 months ago NANOBIOTIX Lance une Étude de Phase 2 sur le Traitement du Cancer du Poumon avec FDA Approval FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
BRIEF published on 05/14/2024 at 22:20, 1 year 8 months ago NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
BRIEF published on 05/14/2024 at 22:15, 1 year 8 months ago GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025 Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
BRIEF published on 05/14/2024 at 22:15, 1 year 8 months ago GENFIT annonce ses résultats financiers du premier trimestre 2024 et dispose d'une trésorerie disponible jusqu'à fin 2025 Industrie Biopharmaceutique Essais Cliniques Baisse Des Revenus Résultats Financiers De GENFIT Situation De Trésorerie
BRIEF published on 05/14/2024 at 22:10, 1 year 8 months ago Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024 Clinical Study Protagonist Therapeutics Rusfertide Polycythemia Vera EHA Congress 2024
BRIEF published on 05/14/2024 at 22:10, 1 year 8 months ago Protagonist Therapeutics présentera de nouvelles données de l'étude Rusfertide au congrès de l'EHA 2024 Étude Clinique Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Congrès EHA 2024
Published on 01/17/2026 at 02:20, 1 day 14 hours ago Core Critical Metals Announces a 1 for 2 Stock Split
Published on 01/16/2026 at 23:19, 1 day 17 hours ago Silver North Announces Further Upsize of Brokered LIFE Private Placement for Gross Proceeds of up to C$10.6 Million
Published on 01/16/2026 at 23:00, 1 day 18 hours ago Silver Spruce Resources Inc. Announces Grant of Options
Published on 01/16/2026 at 22:55, 1 day 18 hours ago Silver Spruce Resources Inc. Announces Closing of $976,000 Non-Brokered Private Placement
Published on 01/18/2026 at 10:55, 6 hours 18 minutes ago World's First Cylindrical Battery Lighthouse Factory: EVE Energy Sets a New Benchmark in Smart Manufacturing
Published on 01/17/2026 at 13:59, 1 day 3 hours ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 01/17/2026 at 13:56, 1 day 3 hours ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 01/16/2026 at 19:07, 1 day 22 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/16/2026 at 18:39, 1 day 22 hours ago Nombre total d'actions et droits de vote - décembre 2025
Published on 01/16/2026 at 18:39, 1 day 22 hours ago Number of shares and voting rights - December 2025 (In French only)
Published on 01/16/2026 at 08:53, 2 days 8 hours ago www.entech-se.com COMMUNIQUÉ DE PRESSE Entech remporte un contrat pour la construction de 400 MWh de stockage d’énergie (BESS) en partenariat avec Eiffage Énergie Systèmes
